Open AccessP668: ACALABRUTINIB VS RITUXIMAB PLUS IDELALISIB OR BENDAMUSTINE IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: ASCEND RESULTS AT ~4 YEARS OF FOLLOW‐UP
Author(s) -
Ghia P.,
Pluta A.,
Wach M.,
Lysak D.,
Simkovic M.,
Kriachok I.,
Illes A.,
Serna J.,
Dolan S.,
Campbell P.,
Musuraca G.,
Jacob A.,
Avery E.,
Lee J. H.,
Usenko G.,
Wang M. H.,
Yu T.,
Jurczak W.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000845556.79615.3f
Subject(s) - bendamustine , medicine , idelalisib , chronic lymphocytic leukemia , gastroenterology , tolerability , rituximab , progression free survival , oncology , ibrutinib , chemotherapy , leukemia , adverse effect , lymphoma